Table 2.
Suspected VAP episode description according to statin exposure and outcome
|
Overall |
Statin previous users |
Statin-naive patients |
P | |
|---|---|---|---|---|
| (n = 349) | (n = 93) | (n = 256) | ||
| Time elapsed between ICU admission and VAP (days) |
10.0 (2.0-157.0) |
10.0 (2.0-72.0) |
10.0 (2.0-157.0) |
0.62 |
| Time elapsed between MV onset and VAP (days) |
10.0 (2.0-156.0) |
10.0 (2.0-69.0) |
10.0 (2.0-156.0) |
0.48 |
| Early VAP (n (%)) |
108 (30.9) |
27 (29.0) |
81 (31.6) |
0.64 |
| Septic shock (n (%)) |
117 (33.6) |
35 (38.0) |
82 (32.0) |
0.29 |
| Appropriate antibiotic therapy (n (%)) |
262 (76.4) |
70 (76.9) |
192 (76.2) |
0.89 |
| Concurrent therapy during VAP period |
|
|||
| Steroids (n (%)) |
153 (45.0) |
41 (45.1) |
112 (45.0) |
0.99 |
| RRT (n (%)) |
83 (24.4) |
29 (31.9) |
54 (21.7) |
0.05 |
| CPIS D1 |
6.0 (2.0-11.0) |
5.0 (2.0-9.0) |
6.0 (2.0-11.0) |
0.32 |
| CPIS D3 |
7.0 (5.0-13.0) |
7.0 (5.0-11.0) |
7.0 (5.0-13.0) |
0.25 |
| SOFA D1 |
8.0 (4.0-17.01) |
9.0 (4.0-16.0) |
8.0 (4.0-17.0) |
0.11 |
| SOFA D3 |
8.0 (4.0-18.0) |
8.0 (4.0-15.0) |
8.0 (4.0-18.0) |
0.63 |
| PCT D-1 |
1.2 (0.1-172.0) |
1.1 (0.1-55.9) |
1.4 (0.1-172.0) |
0.42 |
| PCT D1 |
1.2 (0.1-91.4) |
1.3 (0.1-30.0) |
1.2 (0.1-91.4) |
0.41 |
| PCT D2 |
1.5 (0.1-162.0) |
1.4 (0.1-64.3) |
1.6 (0.1-162.0) |
0.28 |
| PCT D3 |
1.3 (0.1-345.2) |
1.5 (0.1-56.2) |
1.2 (0.1-345.2) |
0.71 |
| PCT D4 |
1.2 (0.1-199.2) |
1.0 (0.1-35.3) |
1.2 (0.1-199.2) |
0.61 |
| Ventilator-free days |
4.0 (0.0-112.0) |
2.0 (0.0-30.0) |
4.0 (0.0-112.0) |
<0.01 |
| Length of ICU stay (days) |
26.0 (4.0-204.0) |
25.0 (4.0-147.0) |
26.0 (5.0-204.0) |
0.80 |
| Duration of MV (days) |
20.0 (2.0-176.0) |
20.0 (2.0-121.0) |
19.0 (2.0-176.0) |
0.42 |
| 30-day mortality (n (%)) | 100 (28.6) | 33 (35.5) | 67 (26.2) | 0.09 |
VAP, ventilator-associated pneumonia; ICU, intensive care unit; MV, mechanical ventilation; RRT, renal replacement therapy; CPIS, clinical pulmonary infection score; D, day; SOFA, sequential organ failure assessment; PCT, procalcitonin.